Abstract YO13
Case summary
Background: Immunoglobulin G4 (IgG4)-related disease is a rare immune-mediated fibroinflammatory condition, characterized by infiltration of IgG4 positive plasma cells and storiform fibrosis. The clinical presentation included fibrosis of affected organs and pseudotumor formation occasionally mimic malignancy.
Aims: To present a case of IgG4-related kidney disease mimicking renal cell carcinoma
Method: Case report
Result: 53-year-old male with an unremarkable previous medical history presented with painless gross hematuria, fever and anemic symptom for 3 months. Laboratory tests showed microcytic anemia, normal creatinine levels and numerous white blood cells in urine. CT chest and abdomen revealed an infiltrative heterogenous hypoenhancing lesion at right kidney size 7.5 x7.9 x8.5cm, a hypoenhancing lesion in hepatic segment IVa/VIII size 6.8x3.8 cm, diffuse intraabdominal lymph node enlargement up to 1.8 cm and multiple lung nodules. The initial clinical and radiologic findings were highly suggestive of malignancy. The differential diagnosis is renal cell carcinoma and lymphoma. Liver biopsy was performed and shown chronic inflammation and fibrosis. Subsequently renal biopsy was done and revealed chronic interstitial nephritis, focal interstitial fibrosis and prominent plasma cell infiltration. Immunohistochemistry from renal biopsy revealed positive for CD20, CD3, CD38, CD138, IgG (210 cells/HPF) and IgG4/IgG-positive cell ratio was 54%. In situ hybridization for kappa and lambda light chain showed polyclonal plasma cell with kappa to lambda ratio of 4:1. Serum IgG4 level was more than 5,840 mg/dL. These findings made diagnosis of IgG4 related kidney disease. Prednisolone 60 mg/day was given and gradually reduced to 10 mg five months thereafter. After 3 months of therapy, a follow-up CT scan showed decrease size of right renal mass to 6.1 x7.3 x6.2 cm, nearly complete resolved of liver lesion and some prior pulmonary nodules.
Conclusion: IgG4 related kidney disease can present with pseudotumor and can be misdiagnosed as a malignant tumor. Awareness of this condition and proper investigation including histopathology and serum IgG4 level should be considered in case of highly suggestive patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract